At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NVCR NovoCure
Trading 04-20 10:46:03 EDT
12.86
+0.03
+0.23%
High13.07Low12.50Vol145.17K
Open12.72D1 Closing12.83Amplitude4.44%
Mkt Cap1.47BTradable Cap1.21BTotal Shares114.00M
T/O1.87MT/O Rate0.15%Tradable Shares94.15M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Novocure Price Target Maintained With a $18.00/Share by Wedbush
Dow Jones  ·  04-16
Novocure Price Target Maintained With a $18.00/Share by Wedbush
NovoCure (NVCR) Gets a Hold from Wedbush
TIPRANKS  ·  04-16
NovoCure (NVCR) Gets a Hold from Wedbush
Tango Therapeutics names Matthew Gall CFO, replacing Daniella Beckman
Reuters  ·  04-15
Tango Therapeutics names Matthew Gall CFO, replacing Daniella Beckman
Assessing NovoCure (NVCR) Valuation After Prolonged Share Price Weakness And Undervalued Narrative
Simply Wall St.  ·  04-14
Assessing NovoCure (NVCR) Valuation After Prolonged Share Price Weakness And Undervalued Narrative
Earning Preview: NovoCure this quarter’s revenue is expected to increase by 14.50%, and institutional views are cautious
Earnings Agent  ·  04-13
Earning Preview: NovoCure this quarter’s revenue is expected to increase by 14.50%, and institutional views are cautious
NovoCure Expands Executive Role, Adjusts CMO Compensation
TIPRANKS  ·  04-10
NovoCure Expands Executive Role, Adjusts CMO Compensation
Novocure pays CHF 5,000 monthly stipend for interim chief medical officer role
Reuters  ·  04-10
Novocure pays CHF 5,000 monthly stipend for interim chief medical officer role
Novocure price target lowered to $16 from $23 at Evercore ISI
TIPRANKS  ·  04-06
Novocure price target lowered to $16 from $23 at Evercore ISI
NovoCure (NVCR) Jumps After Strong PANOVA-4 Data Validates TTFields Combo Potential In Pancreatic Cancer
Simply Wall St.  ·  04-03
NovoCure (NVCR) Jumps After Strong PANOVA-4 Data Validates TTFields Combo Potential In Pancreatic Cancer
Novocure to report first-quarter results, host conference call and webcast
Reuters  ·  04-01
Novocure to report first-quarter results, host conference call and webcast
Novocure to Report First Quarter 2026 Financial Results
THOMSON REUTERS  ·  04-01
Novocure to Report First Quarter 2026 Financial Results
Zymeworks appoints Kristin Stafford as CFO effective April 1, 2026
Reuters  ·  04-01
Zymeworks appoints Kristin Stafford as CFO effective April 1, 2026
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Ongoing Middle East Tensions
MT Newswires Live  ·  03-26
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Ongoing Middle East Tensions
Novocure reports PANOVA-4 primary endpoint met; disease control rate rises to 74.4% from 48% in historical control
Reuters  ·  03-26
Novocure reports PANOVA-4 primary endpoint met; disease control rate rises to 74.4% from 48% in historical control
Novocure Ltd - Ttfields Therapy Well-Tolerated With Device Safety Consistent With Prior Studies
THOMSON REUTERS  ·  03-26
Novocure Ltd - Ttfields Therapy Well-Tolerated With Device Safety Consistent With Prior Studies
Novocure Announces Positive Topline Results From Phase 2 Panova-4 Clinical Trial of Tumor Treating Fields (Ttfields) Therapy for Metastatic Pancreatic Cancer
THOMSON REUTERS  ·  03-26
Novocure Announces Positive Topline Results From Phase 2 Panova-4 Clinical Trial of Tumor Treating Fields (Ttfields) Therapy for Metastatic Pancreatic Cancer
Novocure Ltd - Panova-4 Meets Primary Endpoint With Dcr of 74.4% VS 48% in Historical Control
THOMSON REUTERS  ·  03-26
Novocure Ltd - Panova-4 Meets Primary Endpoint With Dcr of 74.4% VS 48% in Historical Control
Should Japan’s Optune Lua Reimbursement Win Reframe NovoCure’s (NVCR) Access and Utilization Story?
Simply Wall St.  ·  03-10
Should Japan’s Optune Lua Reimbursement Win Reframe NovoCure’s (NVCR) Access and Utilization Story?
NovoCure (NVCR) Is Up 24.5% After FDA Approval Of Optune Pax And 2026 Guidance Update
Simply Wall St.  ·  03-03
NovoCure (NVCR) Is Up 24.5% After FDA Approval Of Optune Pax And 2026 Guidance Update
Japan approves national reimbursement for Novocure's Optune Lua in NSCLC
Reuters  ·  03-02
Japan approves national reimbursement for Novocure's Optune Lua in NSCLC

Introduction

Company Name.
NovoCure
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Issue price:
--